Fundraising Fox
AdvanCell Isotopes
Cambridge, US · Founded 2026 · Delaware corporation · 99 employees on LinkedIn · 9 known investors
Find your way into AdvanCell Isotopes
Sign up to see every warm intro you have to AdvanCell Isotopes
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AdvanCell Isotopes team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung. Its lead-212-based programs, such as ADVC001 for metastatic prostate cancer, are in clinical development.
Founders & leadership
AdvanCell Isotopes was founded in 2026 by Andrew Adamovich.
Board
Investors · 9
How we know: Bain Capital Life Sciences's portfolio page · press coverage · Not right? Tell us
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
How we know: Proto Axiom's portfolio page · Not right? Tell us
How we know: Sanofi Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: SV Health Investors's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: press coverage · funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$533.3M disclosed across 2 rounds · 2026
- $315MSeries DJul 2026Source ↗
▶$218.3MraisedJul 2026 · 41 investors · BiotechnologyRule 506(b)
- Philina LeeExecutive Officer, Director
- Aaron PickettExecutive Officer
- Wing Cheong LamDirector
- Nik EconomopoulosDirector
- Anthony AiudiDirector
- Bali MuralidharDirector
- Jamil BegDirector
- Christopher GagliardiDirector
- Andrew AdamovichDirector
- Andrew KayDirector
- Kevin CameronDirector
- Offering amount
- $315M
- Amount sold
- $218.3M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware, 2026
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as AdvanCell Isotopes.
In the news
AdvanCell has filed a notice of an exempt offering of securities to raise $315 Million in New Funding. - intelligence360intelligence360.news · Aug 2026
AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure - AdvanCelladvancell.com.au · Jul 2026Frequently asked questions
- What does AdvanCell Isotopes do?
- AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung. Its lead-212-based programs, such as ADVC001 for metastatic prostate cancer, are in clinical development.
- Who founded AdvanCell Isotopes?
- AdvanCell Isotopes was founded by Andrew Adamovich in 2026.
- Who are AdvanCell Isotopes's investors?
- AdvanCell Isotopes's investors include Bain Capital Life Sciences, Catalio Capital Management, LP, Proto Axiom, Sanofi Ventures, SV Health Investors, Tenmile, Abingworth, Ally Bridge Group and 1 more.
- How much funding has AdvanCell Isotopes raised?
- AdvanCell Isotopes has disclosed $533.3M raised across 2 rounds.
- Where is AdvanCell Isotopes headquartered?
- AdvanCell Isotopes is headquartered in Cambridge, US.